Errors in Funding/Support, Financial Disclosure, Tables, and Text. FREE

Errors in Funding/Support, Financial Disclosure, Tablęs, and Text. In the Original Article by Merikangas et al titled “Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication,” published in the May issue (2007;64[5]:543-552), there were several errors.

First, the following sentence in the Funding/Support section was incorrect: “The preparation of this article was supported by AstraZeneca.” AstraZeneca did not provide any financial or scientific support for this study.

Second, in addition to the financial disclosure of Dr Hirschfeld, that section should have contained the following: “Dr Akiskal is a consultant to or serves on the advisory board of Abbott International, GlaxoSmithKline, and Sanofi-Aventis. Dr Angst is a consultant to or serves on the advisory board of AstraZeneca and Eli Lilly and Company. Mr Greenberg is a consultant to or serves on the advisory board of AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Ortho Biotech, and Sanofi-Aventis. Dr Kessler is a consultant to or serves on the advisory board of AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi-Aventis, and Wyeth-Ayerst.

Third, Table 1 and Tables 3 through 6 were labeled incorrectly with regard to SD and SE. In Table 1, the mention of SD should have read SE. In Tables 3 through 6, the mentions of SE should have read SD. A corrected version of Table 1 with SDs is available at http://www.hcp.med.harvard.edu/ncs/ftpdir/PA377%20erratum.pdf.

Fourth, the reference to inappropriate pharmacological treatment of bipolar disorder should have been restricted to bipolar disorders I and II and not included subthreshold bipolar disorder.

Errors 3 and 4 were pointed out by Bernard Carroll, MD.